Last reviewed:
Effective treatment has greatly improved life expectancy. A 2023 study of more than 200,000 adults with HIV in Europe and North America estimated that 40-year-olds who started ART in 2015–2019 and survived at least one year had about 39 additional years of life for women and 37 for men. Outcomes were closer to the general population at higher CD4 counts. These are population estimates, not a personal forecast or measurements from a 2026 cohort.[1]
How dramatically the picture changed
Before effective combination treatment, advanced AIDS carried a poor prognosis. That history should not be described as only one or two years of survival after every HIV diagnosis: HIV diagnosis and an AIDS diagnosis are different milestones. Today, early diagnosis, sustained ART and preventive care support long lives. HIV.gov reports that about 54% (597,296) of people with diagnosed HIV in the United States in 2023 were aged 50 or older.[5]
The 18-cohort Antiretroviral Therapy Cohort Collaboration analysis in The Lancet HIV quantified the early gains: between 1996 and 2010, life expectancy for 20-year-olds starting ART rose by about 9 years in women and 10 years in men — roughly a decade for both sexes across Europe and North America[2]. The authors attributed the improvement to less toxic drugs, better adherence, prophylaxis, management of comorbidity, more options after resistance, fewer drug interactions, and screening and prevention programs[2].
The landmark numbers, cohort by cohort
Trickey et al. (2023). The analysis included 206,891 adults and 5,780 deaths during follow-up from 2015. Participants had survived at least one year on ART. Estimated remaining life at age 40 was 39.0 years for women and 37.0 for men who started ART in 2015–2019, versus 35.8 and 34.5 for those who started in 1996–2014. Among 2015–2019 starters, estimates ranged from 24.9 and 23.7 years at CD4 counts of 0–49 cells/µL to 42.0 and 39.2 years at CD4 counts of at least 500, measured at the start of follow-up. These are observational estimates and vary substantially by clinical circumstances.[1]
Kaiser Permanente (Marcus et al.). Comparing about 39,000 adults with HIV to 387,785 matched adults without HIV between 2000 and 2016, the gap in overall life expectancy at age 21 fell from 22.1 years in 2000–2003 to 9.1 years in 2014–2016 (56.0 vs 65.1 years), and narrowed further to 6.8 years among people who started ART with a CD4 count ≥500/µL in 2011–2016[3].
ART-CC (Europe and North America, 2008–2010 starters). For someone starting ART at age 20 with a CD4 count above 350 cells/µL one year later, the estimated age at death was 78.0 years. That is total attained age, not 78 additional years. These historical estimates show major progress but should not be treated as a prediction for an individual starting treatment in 2026.[2][1]
What still drives the remaining gap
Several factors shape the remaining gap, including immune damage, other health conditions and unequal access to care. These studies do not prove that medication effects never contribute to illness.
Late diagnosis. Trickey et al. emphasize the "continuing importance of early diagnosis and sustained treatment of HIV," because estimates for people with low CD4 counts at the start of follow-up were substantially lower[1]. The earlier ART-CC paper likewise called for continued efforts to address late diagnosis and late presentation to care, and to support lifelong adherence[2].
Other health conditions and treatment considerations. The ART-CC authors emphasized prevention and management of comorbidities as well as better treatment and adherence. Older people with HIV commonly face cardiovascular disease, diabetes, kidney disease and cancer; HIV-related inflammation, aging, lifestyle, access to care and medication effects can all be relevant. HIV treatment remains essential, and concerns about adverse effects should prompt a review with the care team rather than stopping ART.[2][5]
Health equity and access. ART-CC called for interventions to promote modern therapy to vulnerable populations, such as people who inject drugs, plus improved access to opioid substitution treatment and direct-acting antivirals for hepatitis C co-infection — and noted that life expectancy was lower in North America than in Europe[2]. aidsmap adds the broader point that social and economic circumstances, income, education and mental wellbeing shape everyone's life expectancy[6]. These are solvable problems, not features of the virus.
Healthy years, not just years
The Kaiser study also estimated years lived without any of six major chronic conditions. At age 21, the gap in these comorbidity-free years was 15.3 years in 2000–2003 and 16.3 in 2014–2016. For 2011–2016, the gap was 9.5 years among people who initiated ART at CD4 counts of at least 500 cells/µL. This is an association in an insured cohort, not proof that early ART alone accounts for the full difference.[3]
In 2011–2016, gaps for individual conditions ranged from 7.4 years for diabetes to 24.5 for chronic liver disease; the cardiovascular-disease gap was 9.0 years. Among those starting ART at CD4 counts of at least 500, the estimated diabetes gap was 1.5 years, with a 95% confidence interval from −0.8 to 3.8. That interval included no difference; the study did not show that the estimated gap literally disappeared. Preventive care—including smoking cessation, blood-pressure and cholesterol management, and liver care—remains part of living well with HIV.[3][6][5]
Treatment is the whole engine — and U=U comes with it
Every one of these gains rests on getting and staying virally suppressed. CDC explains that HIV treatment can make viral load so low a test cannot detect it, and that "most people can get HIV under control within six months"[4]. CDC is also direct about timing: all people with HIV should take treatment regardless of how long they have had HIV or how healthy they feel, because delaying lets HIV keep harming the immune system and raises the chance of getting sick and developing AIDS[4].
Effective ART and maintained viral suppression prevent sexual HIV transmission: U=U. Pregnancy and birth have a different evidence base. Comprehensive treatment and perinatal care reduce transmission to 1% or less, which should not be described as the same zero-risk conclusion as sexual U=U.[7][8][4]
Two caveats worth carrying. aidsmap notes that life expectancy figures are averages calculated by projecting current mortality rates forward, and that we still have limited experience of people living with HIV into their seventies and eighties[6] — while also observing that future improvements in care could mean people live longer than current estimates suggest[6]. And Trickey's estimates describe people already on ART for at least a year, not the untreated population[1]. The number that matters most is not in any paper: it is whether you are diagnosed early, in care, and suppressed.
Related questions
If I start treatment now, can I expect a normal lifespan?
It can be close, especially for people with sustained treatment and high CD4 counts. The 2023 Europe/North America analysis found life expectancy only a few years below the general population in its high-CD4 groups. Results vary by health, access to care and other circumstances; an average cannot predict an individual lifespan.[1]
Does it matter how early I start treatment?
Early diagnosis and effective treatment are associated with better outcomes. In the Kaiser study, people starting ART at CD4 counts of at least 500 cells/µL had smaller overall and comorbidity-free life-expectancy gaps. In Trickey’s analysis, CD4 count at follow-up start also strongly distinguished outcomes. These are different measures and observational comparisons.[1][3]
What should I watch besides HIV itself?
Aging with HIV calls for attention to cardiovascular, kidney and liver disease, diabetes, cancer and other conditions, alongside HIV treatment. The Kaiser study found a particularly large gap in years free of chronic liver disease. Screening and prevention should be tailored to your age, history and clinical risks.[3][5]
Does staying undetectable protect my partners too?
Related from RiseUpToHIV
References & Sources
- Trickey et al., The Lancet HIV (2023) — Life expectancy after 2015 of adults with HIV on long-term ART. Full paper; cohort periods, CD4 strata and estimated remaining years. Source. ↩↩↩↩↩↩ ↩ ↩ ↩
- ART-CC, The Lancet HIV (2017) — Survival of people starting ART between 1996 and 2013. Full paper; historical gains and estimated age at death of 78.0 for the specified subgroup. Source. ↩↩↩↩↩↩
- Marcus et al. — Overall and Comorbidity-Free Life Expectancy With and Without HIV, 2000–2016 (Kaiser Permanente; PMC). Life-expectancy gap fell from 22.1 to 9.1 years; comorbidity-free gap remained about 16 years, narrowing to 9.5 with early ART. ↩ ↩ ↩ ↩ ↩ ↩
- CDC — Treating HIV. Viral suppression within about six months, treatment for everyone regardless of how they feel, and U=U. ↩ ↩ ↩
- HIV.gov — Aging with HIV. Dated 2023 age distribution and health considerations for older people with HIV. Source. ↩↩↩↩ ↩
- aidsmap — Life expectancy for people living with HIV. Plain-language framing of a normal lifespan, social determinants, and the limits of projected averages. ↩ ↩ ↩ ↩
- NIH Perinatal Guidelines — Introduction; comprehensive care lowers perinatal transmission to 1% or less, distinct from sexual U=U. Source. Checked September 21, 2026. ↩ ↩
- NIH Adult and Adolescent ARV Guidelines — Antiretroviral Therapy to Prevent Sexual Transmission of HIV. Source. Checked September 21, 2026. ↩ ↩
Community publications like POZ, Positively Aware, and TheBody inform framing and lived-experience context on RiseUpToHIV. Every clinical, epidemiological, or public-health claim above is anchored to a primary source.